Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer

Publication | Closed Access

DOI

270

Citations

References

2017

Year

Andreas Schneeweiß, Stephen Chia, Tamas Hickish, Vernon Harvey, Alexandru Eniu, Maeve Waldron-Lynch, Jennifer Eng‐Wong, S Kirk, Javier Cortés

European Journal of Cancer

Breast OncologyOncologySafety StudyBreast CancerPharmacotherapyCancer TreatmentMedicineRadiation OncologyLong-term Efficacy AnalysisIi Tryphaena